172 related articles for article (PubMed ID: 35263985)
1. The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.
Decombis S; Papin A; Bellanger C; Sortais C; Dousset C; Le Bris Y; Riveron T; Blandin S; Hulin P; Tessoulin B; Rouel M; Le Gouill S; Moreau-Aubry A; Pellat-Deceunynck C; Chiron D
Haematologica; 2022 Dec; 107(12):2905-2917. PubMed ID: 35263985
[TBL] [Abstract][Full Text] [Related]
2. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
Papin A; Tessoulin B; Bellanger C; Moreau A; Le Bris Y; Maisonneuve H; Moreau P; Touzeau C; Amiot M; Pellat-Deceunynck C; Le Gouill S; Chiron D
Leukemia; 2019 Oct; 33(10):2442-2453. PubMed ID: 30940906
[TBL] [Abstract][Full Text] [Related]
3. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
Chiron D; Bellanger C; Papin A; Tessoulin B; Dousset C; Maiga S; Moreau A; Esbelin J; Trichet V; Chen-Kiang S; Moreau P; Touzeau C; Le Gouill S; Amiot M; Pellat-Deceunynck C
Blood; 2016 Dec; 128(24):2808-2818. PubMed ID: 27697772
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
[TBL] [Abstract][Full Text] [Related]
5. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
6. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells.
Sasaki Y; Calado DP; Derudder E; Zhang B; Shimizu Y; Mackay F; Nishikawa S; Rajewsky K; Schmidt-Supprian M
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10883-8. PubMed ID: 18663224
[TBL] [Abstract][Full Text] [Related]
7. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
Paiva C; Rowland TA; Sreekantham B; Godbersen C; Best SR; Kaur P; Loriaux MM; Spurgeon SEF; Danilova OV; Danilov AV
Haematologica; 2017 Nov; 102(11):1890-1900. PubMed ID: 28838991
[TBL] [Abstract][Full Text] [Related]
8. A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
Araujo-Ayala F; Dobaño-López C; Valero JG; Nadeu F; Gava F; Faria C; Norlund M; Morin R; Bernes-Lasserre P; Serrat N; Playa-Albinyana H; Giménez R; Campo E; Lagarde JM; López-Guillermo A; Gine E; Colomer D; Bezombes C; Pérez-Galán P
Leukemia; 2023 Jun; 37(6):1311-1323. PubMed ID: 37031299
[TBL] [Abstract][Full Text] [Related]
9. BAFF receptor antibody for mantle cell lymphoma therapy.
Zhang K; Roy NK; Vicioso Y; Woo J; Beck R; de Lima M; Caimi P; Feinberg D; Parameswaran R
Oncoimmunology; 2021 Mar; 10(1):1893501. PubMed ID: 33747637
[TBL] [Abstract][Full Text] [Related]
10. Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma.
Mastorci K; Muraro E; Pasini E; Furlan C; Sigalotti L; Cinco M; Dolcetti R; Fratta E
PLoS One; 2016; 11(4):e0153823. PubMed ID: 27123851
[TBL] [Abstract][Full Text] [Related]
11. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells.
Odqvist L; Sánchez-Beato M; Montes-Moreno S; Martín-Sánchez E; Pajares R; Sánchez-Verde L; Ortiz-Romero PL; Rodriguez J; Rodríguez-Pinilla SM; Iniesta-Martínez F; Solera-Arroyo JC; Ramos-Asensio R; Flores T; Palanca JM; Bragado FG; Franjo PD; Piris MA
Clin Cancer Res; 2013 May; 19(9):2319-30. PubMed ID: 23536439
[TBL] [Abstract][Full Text] [Related]
12. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.
Le K; Sun J; Khawaja H; Shibata M; Maggirwar SB; Smith MR; Gupta M
Blood Adv; 2021 Jul; 5(14):2863-2878. PubMed ID: 34297045
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
Pham LV; Tamayo AT; Yoshimura LC; Lo P; Ford RJ
J Immunol; 2003 Jul; 171(1):88-95. PubMed ID: 12816986
[TBL] [Abstract][Full Text] [Related]
15. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.
Pham LV; Vang MT; Tamayo AT; Lu G; Challagundla P; Jorgensen JL; Rollo AA; Ou Z; Zhang L; Wang M; Ford RJ
Leuk Lymphoma; 2015 Jan; 56(1):186-93. PubMed ID: 24611650
[TBL] [Abstract][Full Text] [Related]
16. Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas.
Grégoire M; Guilloton F; Pangault C; Mourcin F; Sok P; Latour M; Amé-Thomas P; Flecher E; Fest T; Tarte K
Oncotarget; 2015 Jun; 6(18):16471-87. PubMed ID: 26158216
[TBL] [Abstract][Full Text] [Related]
17. DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis.
Li Y; Xie X; Jie Z; Zhu L; Yang JY; Ko CJ; Gao T; Jain A; Jung SY; Baran N; Konopleva MY; Cheng X; Sun SC
Blood; 2021 Dec; 138(23):2360-2371. PubMed ID: 34255829
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
[TBL] [Abstract][Full Text] [Related]
19. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.
Zhang L; Yang J; Qian J; Li H; Romaguera JE; Kwak LW; Wang M; Yi Q
Blood; 2012 Nov; 120(18):3783-92. PubMed ID: 22968454
[TBL] [Abstract][Full Text] [Related]
20. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
Papin A; Le Gouill S; Chiron D
Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
